TNF ALPHA ANTAGONIST THERAPY and safety monitoring

Thao Pham , Herve Bachelez (1) , Jean-Marie Berthelot (2) , Jacques Blacher , Yoram Bouhnik , Pascal Claudepierre (3) , Arnaud Constantin , Bruno Fautrel (4) , Philippe Gaudin (5) , Vincent Goeb , Laure Gossec (6) , Philippe Goupille (7) , Severine Guillaume-Czitrom (8) , Eric Hachulla (9) , Isabelle Huet (4) , Denis Jullien (10) , Odile Launay (11) , Marc Lemann (1) , Jean-Francis Maillefert (12) , Jean-Pierre Marolleau , Valerie Martinez , Charles Masson , Jacques Morel (13) , Luc Mouthon (6) , Stanislas Pol (6) , Xavier Puechal , Pascal Richette (14) , Alain Saraux , Thierry Schaeverbeke (15) , Martin Soubrier , Anne Sudre (5) , Tu-Anh Tran (8) , Manuelle Viguier (1) , Olivier Vittecoq , Daniel Wendling , Xavier Mariette (8) , Jean Sibilia

1 Hôpital Saint-Louis
2 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
3 Hôpital Henri Mondor
4 CHU Pitié-Salpêtrière [AP-HP]
5 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
6 Hôpital Cochin [AP-HP]
7 GICC UMR 6239 CNRS - Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011]
8 Hôpital Bicêtre
9 Hôpital Claude Huriez [Lille]
10 Hôpital Edouard Herriot [CHU - HCL]
11 UPD5 - Université Paris Descartes - Paris 5
12 CHU Dijon
13 CHU - Hôpital Lapeyronie [Montpellier]
14 Hôpital Lariboisière
15 Hôpital Pellegrin

Objectives: To develop and/or update fact sheets about TNF alpha antagonists treatments, in order to assist physicians in the management of patients with inflammatory joint disease. Methods: 1. selection by a committee of rheumatology experts of the main topics of interest for which fact sheets were desirable; 2. identification and review of publications relevant to each topic; 3. development and/or update of fact sheets based on three levels of evidence: evidence-based medicine, official recommendations, and expert opinion. The experts were rheumatologists and invited specialists in other fields, and they had extensive experience with the management of chronic inflammatory diseases, such as rheumatoid. They were members of the CRI (Club Rhumatismes et Inflammation), a section of the Societe Francaise de Rhumatologie. Each fact sheet was revised by several experts and the overall process was coordinated by three experts. Results: Several topics of major interest were selected: contraindications of TNF alpha antagonists treatments, the management of adverse effects and concomitant diseases that may develop during these therapies, and the management of everyday situations such as pregnancy, surgery, and immunizations. After a review of the literature and discussions among experts, a consensus was developed about the content of the fact sheets presented here. These fact sheets focus on several points: 1. in RA and SpA, initiation and monitoring of TNF alpha antagonists treatments, management of patients with specific past histories, and specific clinical situations such as pregnancy; 2. diseases other than RA, such as juvenile idiopathic arthritis; 3. models of letters for informing the rheumatologist and general practitioner; 4. and patient information. Conclusion: These TNF alpha antagonists treatments fact sheets built on evidence-based medicine and expert opinion will serve as a practical tool for assisting physicians who manage patients on these therapies. They will be available continuously at www.cri-net.com and updated at appropriate intervals.

Domaines: Sciences du Vivant [q-bio]

Thao Pham, Herve Bachelez, Jean-Marie Berthelot, Jacques Blacher, Yoram Bouhnik, et al.. TNF ALPHA ANTAGONIST THERAPY and safety monitoring. Joint Bone Spine, 2011, 78, pp.15-185. ⟨hal-00618537⟩